News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
JPOD @ Philadelphia: Webinar Recording
Olivia McPherson, Program Manager, JPOD@PHILADELPHIA, shares how the JPOD and Johnson & Johnson's JLABS program helps startups with life science commercialization.
Wellcome Leap Funds Penn to develop “on-demand” manufacturing technology for RNA-based vaccines
Penn Engineering secured a multi-million-dollar contract with Wellcome Leap under the organization’s $60 million RNA Readiness + Response (R3) program.
Webinar Recording: IP Trends for Emerging Penn Engineering Technologies
This webinar discusses the latest trends in intellectual property and patenting for engineers, including robotics, nanotechnology, med-tech and more
Newly discovered ‘encrypted peptides’ with antibiotic properties
A new study reports three distinct proteins in human plasma that have naturally occurring antibiotic properties. Global public health officials are concerned about the r
John Trojanowski, MD, PhD
John Q. Trojanowski, MD, PhD is remembered as a neuroscience pioneer.
Inspiring people, place, and purpose
Gutmann spearheaded the creation of an innovation ecosystem for Penn, Philadelphia, and beyond by transforming technology transfer at Penn to be both more faculty- and industry-friendly.
Penn Startups Raising Capital – Spring 2022
PCI supports and facilitates startup formation and growth through our startup creation programs and our licensing partnerships. This list of Penn affiliated startups are actively fundraising.
Medical device startup Neuralert has big 2022 plans
The device's algorithm maps out asymmetric arm movements or weakness, a tell-tale sign of a stroke, CEO Eric Corkhill said. Here's why he's so excited about its potential.
USPTO launches new Patent Public Search tool and webpage
The USPTO announced a new Patent Public Search tool that provides more convenient, remote, and robust full-text searching of all U.S. patents and published patent applications.
Decade-long remission after CAR T cell therapy
Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.